PDCD1 and melanoma: Genetic and pharmacologic inhibition of myeloid cell receptor tyrosine kinases TYRO3, AXL, and MERTK have been demonstrated to diminish suppressive enzymatic capabilities of MDSCs and augment anti-PD-1 therapy in melanoma in part through regulation of STAT3 serine phosphorylation and nuclear localization (113).